triiodothyronine has been researched along with Hyperlipoproteinemias in 3 studies
Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.
3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.
Hyperlipoproteinemias: Conditions with abnormally elevated levels of LIPOPROTEINS in the blood. They may be inherited, acquired, primary, or secondary. Hyperlipoproteinemias are classified according to the pattern of lipoproteins on electrophoresis or ultracentrifugation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Triamcinolone treatment did not affect plasma protein and albumin levels but increased the level of plasma triglycerides and cholesterol in the very low density lipoprotein (VLDL) and LDL but not high density lipoprotein fractions." | 5.29 | Hyperlipoproteinemia of aminonucleoside-induced nephrotic syndrome--modulation by glucocorticoids and triiodothyronine. ( Shafrir, E, 1996) |
| "Triamcinolone treatment did not affect plasma protein and albumin levels but increased the level of plasma triglycerides and cholesterol in the very low density lipoprotein (VLDL) and LDL but not high density lipoprotein fractions." | 1.29 | Hyperlipoproteinemia of aminonucleoside-induced nephrotic syndrome--modulation by glucocorticoids and triiodothyronine. ( Shafrir, E, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (33.33) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bogner, U | 1 |
| Arntz, HR | 1 |
| Peters, H | 1 |
| Schleusener, H | 1 |
| Shafrir, E | 1 |
| Wilke, H | 1 |
| Regler, B | 1 |
| Keymling, R | 1 |
| Frahm, H | 1 |
1 trial available for triiodothyronine and Hyperlipoproteinemias
| Article | Year |
|---|---|
[Therapy of hyperlipoproteinemia. Additive effect of the lipid-lowering agent d-triiodothyronine during dietetic treatment].
Topics: Diet, Reducing; Fatty Acids, Unsaturated; Humans; Hyperlipoproteinemias; Triiodothyronine | 1979 |
2 other studies available for triiodothyronine and Hyperlipoproteinemias
| Article | Year |
|---|---|
Subclinical hypothyroidism and hyperlipoproteinaemia: indiscriminate L-thyroxine treatment not justified.
Topics: Adolescent; Adult; Age Factors; Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Human | 1993 |
Hyperlipoproteinemia of aminonucleoside-induced nephrotic syndrome--modulation by glucocorticoids and triiodothyronine.
Topics: Animals; Blood Proteins; Fatty Acids, Nonesterified; Glucocorticoids; Gluconeogenesis; Hyperlipoprot | 1996 |